دورية أكاديمية
أعرض في EDS

PLD1 is a key player in cancer stemness and chemoresistance: Therapeutic targeting of cross-talk between the PI3K/Akt and Wnt/β-catenin pathways.

التفاصيل البيبلوغرافية
العنوان: PLD1 is a key player in cancer stemness and chemoresistance: Therapeutic targeting of cross-talk between the PI3K/Akt and Wnt/β-catenin pathways.
المؤلفون: Lim SH; Department of Pharmacy, Yonsei University, Incheon, 21983, Republic of Korea., Lee H; Department of Pharmacy, Yonsei University, Incheon, 21983, Republic of Korea., Lee HJ; Department of Pharmacy, Yonsei University, Incheon, 21983, Republic of Korea., Kim K; Department of Pharmacy, Yonsei University, Incheon, 21983, Republic of Korea., Choi J; Department of Pharmacy, Yonsei University, Incheon, 21983, Republic of Korea., Han JM; Department of Pharmacy, Yonsei University, Incheon, 21983, Republic of Korea.; POSTECH Biotech Center, Pohang University of Science and Technology, Pohang, 37673, Republic of Korea., Min DS; Department of Pharmacy, Yonsei University, Incheon, 21983, Republic of Korea. minds@yonsei.ac.kr.; Yonsei Institute of Pharmaceutical Sciences, College of Pharmacy, Yonsei University, Incheon, 21983, Republic of Korea. minds@yonsei.ac.kr.
المصدر: Experimental & molecular medicine [Exp Mol Med] 2024 Jul; Vol. 56 (7), pp. 1479-1487. Date of Electronic Publication: 2024 Jul 01.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 9607880 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2092-6413 (Electronic) Linking ISSN: 12263613 NLM ISO Abbreviation: Exp Mol Med Subsets: MEDLINE
أسماء مطبوعة: Publication: Jan. 2013- : New York : Nature Publishing Group
Original Publication: Seoul : Korean Society of Medical Biochemistry and Molecular Biology, 1996-
مواضيع طبية MeSH: Phospholipase D*/metabolism , Drug Resistance, Neoplasm* , Proto-Oncogene Proteins c-akt*/metabolism , Wnt Signaling Pathway*/drug effects , Phosphatidylinositol 3-Kinases*/metabolism , Neoplastic Stem Cells*/metabolism , Neoplastic Stem Cells*/pathology, Humans ; Animals ; Neoplasms/metabolism ; Neoplasms/drug therapy ; Neoplasms/pathology ; Molecular Targeted Therapy
مستخلص: The development of chemoresistance is a major challenge in the treatment of several types of cancers in clinical settings. Stemness and chemoresistance are the chief causes of poor clinical outcomes. In this context, we hypothesized that understanding the signaling pathways responsible for chemoresistance in cancers is crucial for the development of novel targeted therapies to overcome drug resistance. Among the aberrantly activated pathways, the PI3K-Akt/Wnt/β-catenin signaling pathway is clinically implicated in malignancies such as colorectal cancer (CRC) and glioblastoma multiforme (GBM). Aberrant dysregulation of phospholipase D (PLD) has been implicated in several malignancies, and oncogenic activation of this pathway facilitates tumor proliferation, stemness, and chemoresistance. Crosstalk involving the PLD and Wnt/β-catenin pathways promotes the progression of CRC and GBM and reduces the sensitivity of cancer cells to standard therapies. Notably, both pathways are tightly regulated and connected at multiple levels by upstream and downstream effectors. Thus, gaining deeper insights into the interactions between these pathways would help researchers discover unique therapeutic targets for the management of drug-resistant cancers. Here, we review the molecular mechanisms by which PLD signaling stimulates stemness and chemoresistance in CRC and GBM. Thus, the current review aims to address the importance of PLD as a central player coordinating cross-talk between the PI3K/Akt and Wnt/β-catenin pathways and proposes the possibility of targeting these pathways to improve cancer therapy and overcome drug resistance.
(© 2024. The Author(s).)
References: Chem Rev. 2011 Oct 12;111(10):6064-119. (PMID: 21936578)
Genes Dev. 2000 Jul 15;14(14):1741-9. (PMID: 10898789)
Cancers (Basel). 2022 Feb 15;14(4):. (PMID: 35205721)
Trends Endocrinol Metab. 2023 Mar;34(3):170-180. (PMID: 36732094)
Nat Microbiol. 2019 Jan;4(1):155-163. (PMID: 30455469)
Pharmacol Ther. 2005 Jun;106(3):357-87. (PMID: 15922018)
Nat Med. 2018 Mar;24(3):262-270. (PMID: 29431745)
Nat Med. 2011 Oct 23;17(11):1514-20. (PMID: 22019887)
Cancer Res. 2017 Jan 1;77(1):142-152. (PMID: 27793841)
Exp Mol Med. 2015 Nov 27;47:e196. (PMID: 26611735)
Biol Rev Camb Philos Soc. 2020 Aug;95(4):911-935. (PMID: 32073216)
BMC Cancer. 2023 Sep 29;23(1):922. (PMID: 37773114)
Int J Cancer. 2006 Sep 1;119(5):1061-6. (PMID: 16570290)
Clin Exp Med. 2011 Jun;11(2):105-12. (PMID: 20809334)
Biochem Pharmacol. 2016 Aug 1;113:36-44. (PMID: 27265143)
Biomed Res Int. 2020 Mar 18;2020:9390878. (PMID: 32258160)
Oncogene. 2003 Jun 19;22(25):3937-42. (PMID: 12813467)
J Thromb Haemost. 2012 Nov;10(11):2361-72. (PMID: 22974101)
Bioorg Med Chem Lett. 2007 Apr 15;17(8):2310-1. (PMID: 17317170)
J Exp Med. 2015 Jul 27;212(8):1219-37. (PMID: 26122663)
Nat Chem Biol. 2020 Apr;16(4):391-399. (PMID: 32042197)
J Cell Physiol. 2021 Jan;236(1):549-560. (PMID: 32869317)
Dev Cell. 2009 Jul;17(1):9-26. (PMID: 19619488)
Cell Signal. 2023 Jan;101:110493. (PMID: 36228964)
Brain Res. 1981 Apr 6;210(1-2):485-92. (PMID: 6261878)
Front Cell Neurosci. 2017 Oct 13;11:318. (PMID: 29081735)
Biochim Biophys Acta. 2009 Sep;1791(9):949-55. (PMID: 19264150)
Nat Rev Drug Discov. 2017 May;16(5):351-367. (PMID: 28209987)
Oncotarget. 2014 May 15;5(9):2428-35. (PMID: 24811082)
J Biol Chem. 2014 Aug 15;289(33):22583-22588. (PMID: 24990952)
J Biol Chem. 2014 Aug 15;289(33):22575-22582. (PMID: 24990948)
Cell Death Dis. 2020 Nov 26;11(11):1013. (PMID: 33243969)
Nature. 1998 Oct 8;395(6702):604-8. (PMID: 9783586)
Am J Physiol Cell Physiol. 2004 Apr;286(4):C747-56. (PMID: 14613891)
Science. 2001 Nov 30;294(5548):1942-5. (PMID: 11729323)
Cancer Res. 2006 Jan 15;66(2):784-93. (PMID: 16424010)
N Engl J Med. 2008 Mar 13;358(11):1148-59. (PMID: 18337604)
J Biol Chem. 2008 Feb 15;283(7):4094-104. (PMID: 18084005)
Nature. 1998 Oct 8;395(6702):608-12. (PMID: 9783587)
Nat Rev Immunol. 2017 Feb;17(2):97-111. (PMID: 27748397)
Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1638-42. (PMID: 15668389)
Oncotarget. 2014 Dec 15;5(23):11857-72. (PMID: 25361009)
PLoS One. 2010 Aug 12;5(8):e12109. (PMID: 20711340)
Cell Rep. 2019 Jan 8;26(2):330-337.e4. (PMID: 30625315)
Biochim Biophys Acta. 2009 Sep;1791(9):850-5. (PMID: 19540930)
ACS Chem Biol. 2015 May 15;10(5):1258-68. (PMID: 25646564)
Nat Chem Biol. 2020 Apr;16(4):400-407. (PMID: 32198492)
Cancer Res. 2011 Jan 15;71(2):293-7. (PMID: 21224347)
J Biol Chem. 2004 Sep 10;279(37):38125-33. (PMID: 15210717)
Cell Stem Cell. 2019 Jan 3;24(1):25-40. (PMID: 30595497)
Nature. 2008 Sep 25;455(7212):552-6. (PMID: 18794899)
Cancer Lett. 2015 Feb 1;357(1):404-411. (PMID: 25434796)
Expert Opin Ther Targets. 2007 May;11(5):707-16. (PMID: 17465727)
J Med Chem. 2013 Mar 28;56(6):2695-9. (PMID: 23445448)
Cell Death Differ. 2014 Apr;21(4):533-46. (PMID: 24317201)
Adv Biol Regul. 2016 May;61:42-6. (PMID: 26695710)
Carcinogenesis. 2009 Feb;30(2):356-65. (PMID: 19126647)
BMB Rep. 2021 Feb;54(2):112-117. (PMID: 32843133)
J Biol Chem. 2014 Aug 15;289(33):22557-22566. (PMID: 24990944)
J Pathol. 2020 Nov;252(3):304-316. (PMID: 32725633)
Nagoya J Med Sci. 2009 Sep;71(3-4):127-36. (PMID: 19994725)
Oncogene. 2007 Mar 15;26(12):1802-10. (PMID: 16964281)
Crit Rev Oncol Hematol. 2023 Feb;182:103920. (PMID: 36702423)
Cancer Res. 2010 May 15;70(10):4233-42. (PMID: 20442281)
Nature. 2008 Sep 25;455(7212):547-51. (PMID: 18794900)
Chin Neurosurg J. 2020 Aug 3;6:25. (PMID: 32922954)
Oncogene. 2013 Jul 25;32(30):3531-42. (PMID: 22890316)
Prog Lipid Res. 2012 Apr;51(2):71-81. (PMID: 22212660)
J Pathol. 2017 Apr;241(5):614-625. (PMID: 28008607)
Cells. 2020 Sep 19;9(9):. (PMID: 32961708)
Nat Cell Biol. 2007 Jun;9(6):706-12. (PMID: 17486115)
Cell Signal. 2008 Dec;20(12):2198-207. (PMID: 18694819)
Nat Med. 2012 Jun;18(6):892-901. (PMID: 22610277)
EMBO J. 2006 Oct 18;25(20):4795-807. (PMID: 17006541)
Prog Lipid Res. 2020 Apr;78:101018. (PMID: 31830503)
J Med Chem. 2010 Sep 23;53(18):6706-19. (PMID: 20735042)
Pharmacol Rev. 2014 Oct;66(4):1033-79. (PMID: 25244928)
Neurooncol Adv. 2019 May-Dec;1(1):vdz042. (PMID: 32309805)
Clin Cancer Res. 2016 Feb 1;22(3):644-56. (PMID: 26224873)
Cancer Res. 2002 Jun 1;62(11):3322-6. (PMID: 12036951)
J Neurol Sci. 2016 Aug 15;367:101-6. (PMID: 27423571)
Cell Physiol Biochem. 2018;48(2):419-432. (PMID: 30021193)
Cell. 2013 Jan 17;152(1-2):25-38. (PMID: 23273993)
Int J Mol Sci. 2022 Feb 24;23(5):. (PMID: 35269660)
Oncogene. 2008 Nov 24;27(55):7047-54. (PMID: 19029944)
Curr Med Chem. 2006;13(10):1169-86. (PMID: 16719778)
Anticancer Res. 2004 Sep-Oct;24(5A):3041-7. (PMID: 15517914)
Exp Mol Med. 2022 Sep;54(9):1563-1576. (PMID: 36131027)
Bioorg Med Chem Lett. 2009 Apr 1;19(7):1916-20. (PMID: 19268584)
Med Oncol. 2011 Sep;28(3):682-8. (PMID: 20373055)
J Biol Chem. 2014 Jan 10;289(2):600-16. (PMID: 24257753)
Clin Cancer Res. 2017 Dec 1;23(23):7340-7350. (PMID: 28939743)
Nat Chem Biol. 2009 Feb;5(2):108-17. (PMID: 19136975)
Cancer Discov. 2013 Sep;3(9):1044-57. (PMID: 23764425)
Theranostics. 2021 Jan 1;11(2):665-683. (PMID: 33391498)
Nat Rev Mol Cell Biol. 2002 Jan;3(1):11-20. (PMID: 11823794)
Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188616. (PMID: 34419533)
المشرفين على المادة: EC 3.1.4.4 (Phospholipase D)
EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
EC 3.1.4.4 (phospholipase D1)
تواريخ الأحداث: Date Created: 20240630 Date Completed: 20240802 Latest Revision: 20240805
رمز التحديث: 20240805
مُعرف محوري في PubMed: PMC11297275
DOI: 10.1038/s12276-024-01260-9
PMID: 38945955
قاعدة البيانات: MEDLINE
الوصف
تدمد:2092-6413
DOI:10.1038/s12276-024-01260-9